What Does Irradiated Blood Mean and Who Needs It?

Irradiated blood is blood that has been exposed to gamma rays or X-rays before transfusion, specifically to destroy donor white blood cells that could otherwise attack a vulnerable recipient’s body. The process targets a rare but almost always fatal complication called transfusion-associated graft-versus-host disease, or TA-GVHD. Not every transfusion patient needs irradiated blood, but for those who do, it can be the difference between a routine recovery and a life-threatening immune crisis.

The Problem Irradiation Solves

When you receive a blood transfusion, you’re getting more than just red blood cells or platelets. Donor blood contains white blood cells, including T lymphocytes, the immune cells that normally help fight infections. In most people, these stowaway donor T cells are quickly recognized and eliminated by the recipient’s own immune system. But in patients whose immune defenses are weakened or absent, those donor T cells can survive, multiply, and begin treating the recipient’s tissues as foreign invaders.

That’s TA-GVHD. The donor’s immune cells attack the recipient’s liver, intestines, skin, lungs, and bone marrow.¹ Unlike the form of graft-versus-host disease seen after bone marrow transplants, TA-GVHD also destroys the patient’s bone marrow, which means the body loses its ability to produce new blood cells. Treatment options are extremely limited, and mortality is far higher than with transplant-related graft-versus-host disease.² Reported fatality rates in TA-GVHD historically exceed 90 percent. That staggering number explains why prevention, rather than treatment, is the entire strategy.

How Irradiation Disables Donor T Cells

The goal isn’t to kill every cell in the blood product. Red blood cells and platelets don’t have a nucleus, so they’re relatively resistant to radiation. T lymphocytes, on the other hand, need intact DNA to divide and mount an immune attack. Gamma or X-ray irradiation damages that DNA severely enough that the T cells can no longer proliferate.

The standard minimum dose used in most countries is 25 gray (2500 cGy), directed at the midplane of the blood product. Research using sensitive proliferation assays has shown this dose is highly effective. At lower doses, some functional T cells survive: a dose of 500 cGy reduces them by roughly a hundredfold, and 1500 cGy pushes that down by nearly ten-thousandfold, but viable T cells can still be detected. At 2500 cGy, no T-cell growth is detectable, representing a reduction of more than about 70,000-fold.³ That’s the threshold regulators have settled on as sufficient to prevent TA-GVHD while preserving the therapeutic value of the blood product itself.

The radiation source is typically cesium-137 or cobalt-60 in a dedicated blood irradiator, though some facilities use linear accelerators (the same machines used in cancer radiotherapy) or standalone X-ray irradiators. The exposure lasts only a few minutes, and the blood product is rotated during the process to ensure the dose is delivered uniformly throughout the bag.⁴

Who Needs Irradiated Blood

The patients who require irradiated cellular blood products share a common thread: their immune systems are unable to recognize and destroy donor lymphocytes. The specific groups are more varied than you might expect.

Bone marrow or stem cell transplant recipients: These patients undergo intense chemotherapy or radiation to destroy their existing bone marrow before receiving a donor graft. During the period when their new immune system is rebuilding, they’re profoundly vulnerable. Irradiated blood is standard for them both before and after transplant.
Patients on certain immunosuppressive drugs: Some chemotherapy regimens, particularly purine analogs like fludarabine, suppress T-cell function so deeply that even an otherwise healthy patient becomes susceptible to TA-GVHD. Patients receiving these drugs typically need irradiated blood regardless of whether they have cancer.
Severe combined immunodeficiency and other congenital immune defects: Infants born with little or no functional immune system are classic candidates. Any cellular blood product they receive should be irradiated.⁵
Fetuses receiving intrauterine transfusions: The fetal immune system is immature enough that donor T cells can engraft easily. Fresh red cells and platelets are irradiated before intrauterine transfusions as a matter of course.
Premature and very low birth-weight neonates: Up to 80 percent of preterm babies weighing less than 1500 grams receive at least one transfusion, often to compensate for blood drawn during monitoring. Their underdeveloped immune systems put them at heightened risk.
Patients receiving blood from relatives: When a donor is a close blood relative, there’s a greater chance the recipient’s immune system will fail to recognize the donor cells as foreign, because the two share enough tissue-type markers that the recipient’s body doesn’t mount a rejection response. Paradoxically, this similarity makes TA-GVHD more likely, not less. Directed donations from family members are therefore routinely irradiated.
Hodgkin lymphoma patients: This cancer and its treatment create a specific pattern of immune dysfunction that makes patients unusually vulnerable to TA-GVHD. Irradiation is generally recommended throughout their treatment and often for life afterward.

Critically ill children with acquired immune deficiency from any cause, not just congenital conditions, are also recommended to receive irradiated blood products.⁵ The common misconception is that only profoundly immunosuppressed patients are at risk. In reality, certain genetic situations (like receiving blood from a donor who happens to share one set of tissue-type markers, known as HLA-homozygous donors) can put even immunocompetent patients at risk, though such events are rare and unpredictable.

What Irradiation Does to the Blood Itself

Irradiation is not a free lunch. While it’s essential for preventing TA-GVHD, it does affect the quality of stored blood products, particularly red blood cells. The most clinically relevant change involves potassium.

Red blood cells maintain a careful balance of potassium inside and sodium outside. Irradiation damages the cell membrane enough to increase potassium leakage into the surrounding fluid. This happens in all stored red cells over time, but irradiation accelerates it considerably. In one study, potassium levels in irradiated red cell units were roughly double those in non-irradiated units by the end of storage, around 60 millimoles per liter compared to 38.⁶ The potassium rise is measurable within 24 hours and becomes pronounced by about a week after irradiation.⁷

The increase in extracellular potassium is dose-dependent and accelerates the longer the irradiated units sit in storage.⁶ For most adult recipients, this extra potassium is absorbed and regulated by the body without issue. But for neonates, very small children, and patients receiving large-volume transfusions, the potassium load can be dangerous. Rapid infusion of high-potassium blood can trigger cardiac arrhythmias. That’s why many blood banks limit the shelf life of irradiated red cells to 28 days from the date of irradiation (compared to the standard 42-day shelf life for non-irradiated units), and why irradiated units destined for neonates are often used within days of irradiation or washed to remove the excess potassium before transfusion.

Irradiation also modestly increases hemolysis, the breakdown of red blood cells, and raises levels of lactate dehydrogenase, an enzyme released when cells are damaged.⁷ These effects are generally minor enough that they don’t compromise the transfusion’s effectiveness for most patients, but they’re worth monitoring in vulnerable populations.

Platelets Handle Irradiation Better Than Red Cells

Platelets are the other major cellular blood component that gets irradiated for at-risk patients. The good news is that they tolerate the process better than red blood cells. Studies measuring platelet quality markers over a standard seven-day storage period found no significant differences between irradiated and non-irradiated platelet concentrates, whether irradiation happened on day one or day five of storage.⁸

Some laboratory research has shown that irradiation increases oxidative stress markers in stored platelets and may slightly accelerate their activation over time.⁹ Whether this translates to a clinically meaningful difference in how well the platelets work after transfusion isn’t well established. In practice, irradiated platelets are considered functionally equivalent to non-irradiated ones for clinical use, and their expiration date is not shortened the way red cell units’ often are.

Why Filtering Out White Cells Isn’t Enough

A question that comes up frequently is whether leukoreduction, the process of filtering white blood cells out of donated blood, can replace irradiation. Many countries now perform universal leukoreduction, removing the vast majority of white cells from blood products before they reach the patient. This step reduces febrile transfusion reactions, lowers the risk of certain viral transmissions, and decreases HLA sensitization. But it doesn’t eliminate TA-GVHD risk.

The problem is a numbers game. Leukoreduction filters reduce white blood cell counts dramatically, but they can’t remove every single T cell. Even a tiny residual population of viable T lymphocytes, in the right immunosuppressed host, can expand and cause disease.¹⁰ Irradiation doesn’t need to physically remove those remaining cells. It just needs to wreck their DNA badly enough that they can’t divide. The two approaches address the problem at different stages: filtration reduces the number of white cells, and irradiation ensures the survivors can’t proliferate. For high-risk patients, irradiation remains the standard of care even when leukoreduction has already been performed.

Pathogen Reduction Technology as an Emerging Alternative

An increasingly discussed alternative to irradiation is pathogen reduction technology, or PRT. These systems use a chemical agent (such as amotosalen, riboflavin, or amustaline) combined with UV light to crosslink DNA and RNA in any nucleated cell or pathogen present in the blood product. The result is similar to irradiation: T cells can no longer replicate. But PRT also inactivates bacteria, viruses, and parasites that might be present in the donation, which irradiation does not do.

Several regulatory authorities and professional societies have approved certain PRT systems as an acceptable substitute for irradiation when it comes to preventing TA-GVHD. Laboratory studies comparing the two approaches have found PRT’s effect on T-cell inactivation to be equivalent or even superior to gamma irradiation, a finding supported by both cell-culture experiments and animal models.¹¹ One recent review noted that PRT is more effective at inactivating leukocytes than current irradiation methods, and that blood products treated with approved PRT systems are already exempt from irradiation requirements in some jurisdictions.¹²

Currently, PRT for platelets is the most mature application, with approved systems in widespread clinical use. PRT for red blood cells and whole blood is still in development.¹¹ Japan, the only country that universally irradiates all cellular blood components, has been a particular focus of interest for PRT as a potential replacement. The appeal is clear: one treatment step that prevents TA-GVHD and also reduces pathogen transmission risk could simplify blood bank operations and eliminate the need for dedicated irradiation equipment.

How Blood Banks Verify the Dose

Because under-irradiation could leave viable T cells in the product and over-irradiation could unnecessarily damage the blood cells, quality control in blood irradiation is rigorous. Blood banks use dosimeters, small devices placed inside or alongside the blood bags, to verify that each unit receives the intended radiation dose.

Thermoluminescent dosimeters are one well-established system: tiny crystalline pellets that absorb radiation energy and release it as measurable light when heated afterward, giving a precise reading of the dose delivered.¹³ Other approaches include radiochromic film indicators, which change color in proportion to the dose received. These are sometimes included in the blood bag itself as a visual check: staff can see at a glance whether irradiation occurred and whether the dose was in the expected range. Polymer gel dosimetry systems have also been validated for mapping the three-dimensional dose distribution inside blood bags and syringes.¹⁴

Irradiators that use sealed radioactive sources also require regular safety testing, including wipe tests to check for surface contamination and ensure the integrity of the source. These are mandatory regulatory requirements in most countries, and the testing frequency depends on national guidelines and the irradiator manufacturer’s specifications.¹³

What About Plasma and Cryoprecipitate

An important point that sometimes gets lost: irradiation applies to cellular blood components, meaning products that contain viable nucleated cells. Fresh frozen plasma and cryoprecipitate are acellular products. They’ve been frozen, which destroys any lymphocytes that may have been present. For this reason, plasma and cryoprecipitate do not require irradiation, even for patients who need their red cells and platelets irradiated. Granulocyte concentrates, on the other hand, are heavily cellular and are always irradiated before transfusion when indicated, regardless of the recipient’s immune status, because of the extremely high white cell content.

Cost and Access Considerations

Dedicated blood irradiators are expensive pieces of equipment, and their use of radioactive sources raises security and regulatory burdens. Not every hospital or blood bank has one on site, which can create logistical challenges. Smaller or rural facilities may need to send blood products to a regional center for irradiation or use a hospital’s existing radiotherapy equipment as an alternative.

One analysis of a facility using a linear accelerator for blood irradiation rather than a dedicated device found the combined direct and indirect costs to be under one euro per bag, including dosimetric verification, personnel time, and equipment depreciation.¹⁵ Per-unit costs are modest, but the upfront capital investment for a standalone irradiator, or the scheduling logistics of sharing radiotherapy equipment, can be a hurdle for facilities with limited resources. This is one reason PRT is attracting interest: if a single chemical treatment can replace both irradiation and some pathogen screening steps, the workflow savings could be substantial.

Irradiated Blood in Veterinary Medicine

Blood transfusion is a growing part of veterinary critical care, and the question of whether animal patients face the same risks from donor white blood cells has started to receive attention. Interestingly, TA-GVHD has been produced experimentally in dogs but hasn’t been convincingly documented as a naturally occurring clinical problem in veterinary patients.¹⁶

Laboratory studies of irradiated canine blood show the same potassium leakage and hemolysis patterns seen in human blood, with rapid increases in extracellular potassium and pH changes after irradiation, and worsening storage lesions over time.¹⁶ Based on these findings, researchers have suggested that if irradiation is used for canine blood, combining it with leukoreduction and administering the product promptly after irradiation would be the safest approach. Dogs receiving immunosuppressive therapy, particularly purine analogs, have been identified as a population that might theoretically benefit from irradiated transfusions, though clinical evidence is still lacking. The field is in its early stages, and routine irradiation of veterinary blood products is not yet standard practice anywhere.